Articles tagged with Pancreatic Tumors
Researchers at UCSF have discovered a new therapeutic target, SRC, present on up to half of all tumors, which can be targeted with antibody drugs. The enzyme, normally hidden inside cells, is exposed on the surface of tumor cells due to an overactive disposal system, making it an easy target for cancer-killing antibodies.
Researchers at UT Health San Antonio successfully used radiofrequency ablation to treat a patient with pancreatic cancer, achieving the first-ever less-invasive procedure in South Texas. The treatment has shown promising results in shrinking tumors and easing symptoms, potentially improving patient outcomes.
Researchers developed an RNA-based therapeutic strategy targeting mutant KRAS genes, stimulating the immune system to attack tumours. The treatment, combining antisense oligonucleotides and immunomodulatory RNA, effectively killed cancer cells in laboratory studies, reducing tumour burden and extending survival.
A phase 1 trial has investigated the combination of a ribonucleotide reductase inhibitor with lutetium Lu 177 dotatate, showing potential for improved treatment outcomes in patients with progressive GEP-NETs. The results have led to a planned phase 2 randomized trial to assess progression-free survival.
Researchers developed a new imaging method using multiphoton microscopy to rapidly identify pancreatic neuroendocrine tumors with high accuracy. Machine learning algorithms achieved 80.6% accuracy, while convolutional neural networks outperformed with accuracies ranging from 90.8% to 96.4%.
The ESMO Gastrointestinal Cancers Congress 2025 will cover topics such as molecular prevention and precision therapy, patient-centred approaches and quality of life. Key findings include the efficacy and safety of combined immunotherapy for hepatocellular carcinoma and colorectal cancer.
Researchers discuss advancements in pancreatic cancer detection using biomarkers, imaging techniques, and molecular diagnostics. Novel therapies targeting the tumor microenvironment and immune evasion mechanisms are explored to improve survival outcomes.
A predictive model combining tumor marker readings with patients' genetic profiles enhances predictions for patient survival and surgery decision-making. The new tool accurately identifies candidates who would benefit from surgery, suggesting that current tumor marker evaluations are inadequate for these genetic profiles.
Researchers at MD Anderson Cancer Center present promising results from clinical trials in three minisymposia abstracts. The studies explore personalized vaccine combination therapy for colorectal cancer, radiotherapy to avoid toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancrea...
A recent study discovered that simultaneously targeting PIKfyve and KRAS-MAPK can eliminate tumors in preclinical human and mouse models. This approach shows promise for treating pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, which is challenging to treat due to its cellular environment.
Researchers developed DNA origami structures that selectively deliver fluorescent imaging agents to pancreatic cancer cells, enabling more accurate cancer imaging and selective chemotherapy delivery. The study also explored the use of origami-folded DNA molecules loaded with chemotherapy drugs for targeted delivery to cancer cells.
A team of researchers has identified a novel oncometabolite that accumulates in tumors and impairs immune cells' ability to fight cancer. The study highlights how the metabolic environment of tumors influences T cell function, opening new possibilities for improving cancer immunotherapy by targeting tumor metabolism.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center are presenting new findings on combination therapies for liver and pancreatic cancers, including a new organoid model for personalized head and neck cancer treatment. Additionally, they are discussing the potential of liquid biopsies for cancer detection and monitoring.
A study reveals that Galectin-1 protein, located in fibroblast nuclei, promotes tumor growth and resistance to treatment. The protein regulates gene expression at a specific level, activating KRAS, a key driver of uncontrolled growth and tumor aggressiveness.
Researchers have developed a new method to identify and classify pancreatic cancer cell subtypes by analyzing sugar molecules on the surface of cells. This approach may lead to more precise diagnoses and better treatment options for patients.
A Rice University-led team developed an implantable 'cytokine factory' that triggers potent immune responses against hard-to-treat cancers. The IL-12 cytokine factory successfully induces the recruitment of tumor-targeting T cells, eliminating local and distal tumors in preclinical models.
Researchers found that FGFR2 expression was higher in KRAS-mutated precancerous lesions and some KRAS-mutated PDAC tumors. Inactivation of FGFR2 delayed KRAS-mutated PDAC development in mice, suggesting a potential role for FGFR2 in driving cancer progression.
Scientists have found a way to effectively 'intercept' pancreatic cancer by targeting the KRAS and FGFR2 genes. This approach slows tumor formation and reduces the number of 'early versions' of cancer in the pancreas. Researchers believe this therapy could be a game-changer for patients with a family history of pancreatic cancer.
Researchers found that detectable mutant KRAS circulating tumor DNA (ctDNA) indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma. The study suggests that ctDNA assays should be performed prior to treatment to have the highest yield.
A new type of RAS inhibitor, daraxonrasib (RMC-6236), has shown significant promise when combined with immunotherapy in preclinical models of pancreatic cancer. The study found that the treatment not only inhibited tumor growth but also reshaped the tumor microenvironment to make it more receptive to immunotherapy.
Researchers at MD Anderson have made significant breakthroughs in understanding pancreatic cancer's evolutionary process and developing new treatment strategies. They also discovered that surgical resection can enhance antitumor response in patients receiving immune checkpoint therapy for advanced kidney cancer.
Researchers found that pancreatic cancer cells gain a survival edge by carrying copies of critical cancer genes on circular pieces of DNA outside chromosomes. The discovery highlights the importance of targeting extrachromosomal DNA in treating the disease.
The study found that Black patients have a higher prevalence of PD-L1 overexpression, TP53 mutations, and KRASG12R mutations compared to White patients. This could affect how their cancer progresses and responds to treatment.
Researchers developed a nanoparticle that delivers an mRNA vaccine targeting a KRAS antigen, boosting the immune response against pancreatic cancer. Experiments in mice showed inhibited and prevented tumor growth, as well as long-term protection against recurrence.
Researchers at MD Anderson Cancer Center have identified biomarkers for predicting treatment response in metastatic breast cancer and found a potential target for tumor progression in pancreatic cancer. Additionally, they discovered that abnormal chromosome changes predict survival in patients with secondary acute myeloid leukemia.
Researchers discovered that pancreatic cancer reprograms nerve cells to promote tumor growth. Blocking nerve function inhibited cancer growth and increased sensitivity to certain therapies.
Researchers have created an immune map for pancreatic cancer, showing why some tumours are more susceptible to macrophage-based therapies. The study identifies potential avenues for improved treatment approaches, including boosting certain cell responses and depleting suppressive immune cells.
Researchers at UCSF used CRISPR gene editing technology to transform ordinary white fat cells into 'beige' fat cells that voraciously consume calories to make heat. Implanted near tumors, these cells outcompeted cancer cells for nutrients, beating back five types of cancer in lab experiments.
Researchers at UCSF describe how to curb MYC levels by disrupting the protein assembly line controlled by RBM42. Disrupting RBM42 in pancreatic cancer cells stopped them from growing, suggesting drugs could be developed to do the same for other fast-growing cancers.
A novel approach transforms treatment for pancreatic cancer by repurposing WR-2721 to protect healthy tissue from radiation damage. Phase 1 and 2 clinical trials are underway to evaluate the safety and efficacy of the new therapy, which could add years of survival to patients.
Researchers studied the prognostic power of micropapillary patterns in PDAC, finding that even small percentages serve as independent prognostic factors for decreased survival. The study suggests incorporating micropapillary pattern percentage into pathology reports could enhance patient management strategies.
A research team at Memorial Sloan Kettering Cancer Center has identified a novel molecular pathway leading to the formation of tertiary lymphoid structures (TLSs) in tumors. TLSs are immune cell clusters that can boost the local immune response and may be harnessed for immunotherapy treatments.
Researchers discovered a key role for neutrophils in cancer cell colonization of abdominal fat through the release of DNA webs called NETs. Additionally, a new biomarker study found that dose-dense chemotherapy improved disease-free survival by 20% and overall survival by 15% for women with early-stage ER-positive breast cancer.
Researchers at University of California San Diego have identified MICAL2 enzyme as a promising target for pancreatic cancer treatment. The study found that excessive production of the enzyme promotes tumor growth and spread in pancreatic ductal adenocarcinomas.
Researchers at TUM have grown tumor organoids that reproduce the morphological complexity of pancreatic cancer cells in the laboratory. The team used machine learning to categorize the organoids into different phenotypes based on their appearance and behavior, which react differently to treatments.
A pioneering study of 192 Brazilian patients with pancreatic ductal adenocarcinoma identified genetic variants associated with the disease. The researchers found that 6.25% had pathogenic germline variants in genes predisposing to pancreatic cancer, and 13% had variants in genes associated with limited or previously unknown associations.
Researchers at Sanford Burnham Prebys found that pancreatic cancer cells rely on a specific nutrient, glutamine, to fuel their unchecked growth. The study identified two enzymes, aPKC zeta and iota, that play a regulatory role in the process of macropinocytosis, allowing cancer cells to scavenge alternative resources.
Researchers at the University of Konstanz have discovered that different mutations of the tumour suppressor p53 affect pancreatic carcinomas differently. The study found that two variants of p53 selectively control distinct metabolic pathways, providing new insights into cancer development.
Researchers found that tumor cell secreted DNA in extracellular vesicles acts as a 'danger' signal to activate an anti-tumor response in the liver, reducing liver metastasis risk. The discovery improves understanding of cancer progression and anticancer immunity.
Dr. Direna Alonso-Curbelo's ERC Consolidator Grant project, IGNITE, aims to unravel the complex interplay between genetic and non-genetic factors that ignite tumor development. The research focuses on understanding how inflammation drives pancreatic cancer initiation and progression.
A new combination of immunotherapy and epigenetic drug may transform resistant pancreatic tumors into susceptible ones, according to a study by Johns Hopkins Medicine researchers. The treatment showed promise in a subset of patients, with tumor shrinkage and durable responses observed over several months.
Researchers at UC Riverside develop a novel method to degrade the Pin1 protein, which is involved in pancreatic cancer development. The 'molecular crowbar' strategy has the potential to target and break down harmful proteins, offering new hope for cancer therapy.
Research highlights the role of gut dysbiosis in pancreatic ductal adenocarcinoma (PDAC), with specific microbial profiles associated with PDAC. Fecal microbiota transplantation (FMT) is proposed as a potential adjunct therapy to improve patient outcomes through microbiome modulation and immune system recalibration.
The World Health Organization's seven-tiered system standardizes the reporting of pancreaticobiliary cytopathology, providing a framework for guiding interpretation of cytology samples and their clinical management. Ancillary testing plays a crucial role in enhancing diagnostic precision, especially in challenging cases.
Researchers document remarkable response to pembrolizumab in patient with metastatic adenosquamous pancreatic cancer (ASCP) and KRAS G12C mutation. The study highlights potential shift in treatment of ASCP, a rare form of pancreatic cancer traditionally underserved by current therapies.
Researchers discovered that INPP4B drives the movement of lysosomes to the periphery of pancreatic cancer cells, releasing their contents into the extracellular space and disrupting the structural support network. This process enables the cells to migrate and invade other tissues, making it easier for the cancer to spread.
Researchers developed a new PET scan that accurately visualizes benign tumors in the pancreas, known as insulinomas, which can cause low blood sugar levels. The Exendin-PET scan uses a substance found in lizard saliva to detect these tumors, improving diagnosis and treatment outcomes.
A multicenter study found that specific KRAS mutations in pancreatic cancer can affect patient outcomes, with some variants associated with better overall survival. The research suggests revising clinical guidelines to recommend routine molecular testing in all patients with pancreatic cancer.
Researchers discovered a key molecule, PAF, that controls the destiny of immune cells and turns them against cancer. The study highlights the importance of targeting PAF to develop new therapies for various types of cancer.
The study used spatial transcriptomics and machine learning to analyze gene expression and cell distribution in PanINs, identifying key features of pancreatic cancer progression. Key findings include increased cell proliferation and decreased inflammatory signaling in high-grade PanIN lesions.
Researchers have developed a novel nanoparticle drug-delivery system to activate an immune pathway in combination with tumor-targeting agents, showing promising results in treating pancreatic cancer. Eight out of nine mice tested experienced tumor improvements, including two complete responses.
Researchers have discovered a new approach to treating pancreatic ductal adenocarcinoma (PDAC), a rare type of pancreatic cancer. Folinic acid has been found to weaken the cancer's defenses by elevating levels of anti-cancer immune molecules, enabling a more effective immune response and slower tumor growth.
Scientists discovered a way to kill pancreatic cancer in mice by combining a ketogenic diet with an existing cancer drug. The diet blocks the cancer's only source of fuel, allowing the drug to take effect and shrink tumors. This finding opens a new vulnerability for treating cancer with diet and personalized therapies.
A new method for detecting pancreatic cancer has been introduced using glycopeptide probes that selectively detect specific antibodies in blood samples. These probes mimic tumor-associated antigens and show promise for early detection screenings.
Cancer cells can attach themselves to liver cells when specific proteins are present, allowing them to colonize and form new tumors. This discovery provides insights into the metastatic process and may lead to potential treatments that prevent cancer from establishing new tumors.
Researchers identified nidogen-2 as a key driver of pancreatic cancer progression and metastasis. Blocking this molecule enhanced chemotherapy effectiveness and reduced spread in mouse models, suggesting a promising new treatment approach.
A study led by UPF describes the mechanism behind insulinoma formation, a rare type of pancreatic beta cell tumor. The research reveals that a change in the epigenetic pattern of beta cells leads to the accumulation of mutations and excessive insulin production.
A new study found that nearly five percent of pancreatic adenocarcinoma patients achieve a pathological complete response (pCR) after treatment, leading to a 63% 5-year survival rate. The research highlights the importance of tailoring treatment based on factors such as chemotherapy regimens and radiation therapy.
Researchers found that ARID1A mutation renders tumors sensitive to immunotherapy by triggering an antiviral immune response. This could lead to improved patient outcomes and the development of targeted therapies.
Researchers at the University of Wisconsin-Madison have developed a novel approach to treating pancreatic cancer using nano-drugs delivered via bacteria. The treatment bypasses the dense collagen barrier surrounding tumors, allowing for more effective delivery of immunotherapies.